Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Tonix Pharma ( (TNXP) ).
On December 29, 2025, Tonix Pharmaceuticals announced updated plans for its TNX-4800 Lyme disease prophylaxis program, including a scheduled 2026 meeting with the U.S. Food and Drug Administration to explore Phase 2/3 development options and the potential use of a controlled human infection model involving Borrelia-infected ticks to demonstrate efficacy. The company reported results from a randomized, double-blind, dose-escalation study in 44 healthy adults showing that single subcutaneous doses up to 10 mg/kg were generally safe and well tolerated, with mostly mild or moderate adverse events, rapid systemic absorption, long-lasting serum levels measurable for up to 12 months, low incidence of anti-drug antibodies, and drug exposure well below levels associated with toxicity in animal studies, underscoring TNX-4800’s potential as an annually administered alternative to traditional Lyme vaccines and signaling a strategic step toward later-stage clinical development.
The most recent analyst rating on (TNXP) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
Tonix Pharma’s overall score is driven by its financial challenges and neutral technical indicators. However, recent corporate events suggest potential for future growth. The negative valuation metrics weigh heavily on the score.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company developing product candidates in infectious disease, including TNX-4800, a monoclonal antibody-based prophylactic treatment intended to protect against Lyme disease caused by Borrelia burgdorferi.
Average Trading Volume: 734,222
Technical Sentiment Signal: Sell
Current Market Cap: $191.5M
See more data about TNXP stock on TipRanks’ Stock Analysis page.